vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $154.2M, roughly 1.2× BridgeBio Pharma, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs -126.2%, a 174.2% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs -21.9%).
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
BBIO vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $188.3M |
| Net Profit | $-194.6M | $90.3M |
| Gross Margin | 94.7% | 79.5% |
| Operating Margin | -90.5% | 32.3% |
| Net Margin | -126.2% | 47.9% |
| Revenue YoY | 2521.2% | -21.9% |
| Net Profit YoY | 27.2% | 1710.8% |
| EPS (diluted) | $-1.00 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.2M | $188.3M | ||
| Q3 25 | $120.7M | $215.3M | ||
| Q2 25 | $110.6M | $188.2M | ||
| Q1 25 | $116.6M | $197.2M | ||
| Q4 24 | — | $241.0M | ||
| Q3 24 | — | $225.5M | ||
| Q2 24 | — | $256.0M | ||
| Q1 24 | $211.1M | $263.4M |
| Q4 25 | $-194.6M | $90.3M | ||
| Q3 25 | $-184.9M | $91.1M | ||
| Q2 25 | $-183.8M | $139.5M | ||
| Q1 25 | $-169.6M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | — | $-284.4M | ||
| Q2 24 | — | $-433.6M | ||
| Q1 24 | $-36.2M | $-49.2M |
| Q4 25 | 94.7% | 79.5% | ||
| Q3 25 | 94.6% | 83.7% | ||
| Q2 25 | 96.7% | 81.3% | ||
| Q1 25 | 97.7% | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | 99.7% | 85.3% |
| Q4 25 | -90.5% | 32.3% | ||
| Q3 25 | -120.3% | 30.4% | ||
| Q2 25 | -121.4% | 5.7% | ||
| Q1 25 | -89.5% | -31.2% | ||
| Q4 24 | — | -69.2% | ||
| Q3 24 | — | -36.4% | ||
| Q2 24 | — | -90.8% | ||
| Q1 24 | 0.2% | -6.1% |
| Q4 25 | -126.2% | 47.9% | ||
| Q3 25 | -153.2% | 42.3% | ||
| Q2 25 | -166.2% | 74.1% | ||
| Q1 25 | -145.4% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -126.1% | ||
| Q2 24 | — | -169.4% | ||
| Q1 24 | -17.1% | -18.7% |
| Q4 25 | $-1.00 | $2.78 | ||
| Q3 25 | $-0.95 | $2.91 | ||
| Q2 25 | $-0.95 | $4.50 | ||
| Q1 25 | $-0.88 | $-0.39 | ||
| Q4 24 | — | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | — | $-14.35 | ||
| Q1 24 | $-0.20 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $226.6M |
| Total DebtLower is stronger | $2.0B | $1.4B |
| Stockholders' EquityBook value | $-2.1B | $-171.5M |
| Total Assets | $936.0M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $570.1M | $226.6M | ||
| Q3 25 | $643.0M | $184.2M | ||
| Q2 25 | $756.9M | $267.4M | ||
| Q1 25 | $540.6M | $138.3M | ||
| Q4 24 | — | $146.9M | ||
| Q3 24 | — | $159.2M | ||
| Q2 24 | — | $236.9M | ||
| Q1 24 | $519.7M | $190.7M |
| Q4 25 | $2.0B | $1.4B | ||
| Q3 25 | $2.0B | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-2.1B | $-171.5M | ||
| Q3 25 | $-1.9B | $-260.5M | ||
| Q2 25 | $-1.8B | $-351.7M | ||
| Q1 25 | $-1.6B | $-496.8M | ||
| Q4 24 | — | $-488.2M | ||
| Q3 24 | — | $-497.6M | ||
| Q2 24 | — | $-218.3M | ||
| Q1 24 | $-1.0B | $228.4M |
| Q4 25 | $936.0M | $1.7B | ||
| Q3 25 | $998.3M | $1.7B | ||
| Q2 25 | $1.1B | $1.5B | ||
| Q1 25 | $881.6M | $1.5B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | $849.3M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | $26.2M |
| Free Cash FlowOCF − Capex | $-56.5M | — |
| FCF MarginFCF / Revenue | -36.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-56.4M | $26.2M | ||
| Q3 25 | $-109.6M | $-60.6M | ||
| Q2 25 | $-80.7M | $-25.6M | ||
| Q1 25 | $-199.2M | $184.0K | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $111.5M | ||
| Q1 24 | $-219.5M | $135.4M |
| Q4 25 | $-56.5M | — | ||
| Q3 25 | $-110.0M | — | ||
| Q2 25 | $-81.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-220.2M | — |
| Q4 25 | -36.6% | — | ||
| Q3 25 | -91.2% | — | ||
| Q2 25 | -73.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -104.3% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBIO
Segment breakdown not available.
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
